Key result
Metabolic syndrome was not significantly associated with overall survival in patients with glioblastoma, with a median survival of 19.7 months versus 17.7 months in those without the syndrome.
Why the study?
The association between metabolic syndrome and glioblastoma is undetermined, with limited data on whether metabolic syndrome affects survival outcomes in glioblastoma patients.
Does metabolic syndrome affect overall survival and progression-free survival in patients with glioblastoma?
Cohort (n=180)
No
Does metabolic syndrome affect overall survival and progression-free survival in patients with glioblastoma?
Metabolic syndrome did not show significant prognostic relevance in glioblastoma patients, though there was a non-significant trend towards increased survival.
Answers are grounded in this paper and cite their sources.
Metabolic syndrome may worsen glioblastoma survival; leaves open independent prognostic value pending prospective validation.
Background Several studies point to metabolic syndrome as a risk factor for the development and progression of several types of cancer. Its association with glioblastoma has yet to be determined, and only two studies investigate the impact of metabolic syndrome on the survival of glioblastoma patients, indicating a trend toward decreased survival in patients with metabolic syndrome. The aim of this study was to determine whether patients with glioblastoma and metabolic syndrome had a worse clinical outcome. Methods We retrospectively reviewed the clinical records of 180 patients diagnosed with glioblastoma. Metabolic syndrome was defined according to the American Heart Association, as the presence of at least three of the following criteria: diabetes, hypertension, hyperlipidemia, and obesity. We analyzed the overall survival and progression-free survival of patients with and without metabolic syndrome. Results Of 180 patients, 20 (11.1%) met the diagnostic criteria for metabolic syndrome. The overall survival of patients with metabolic syndrome was 19.8 months, and without metabolic syndrome was 17.7 months (p-value=0.085). The progression-free survival of patients with metabolic syndrome was 9.9 months, and without metabolic syndrome was 7.9 months (p-value=0.076). Conclusion Our results showed no prognostic relevance of metabolic syndrome in patients with glioblastoma, although there was a trend towards increased overall survival and progression-free survival in patients with metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Lucas et al. (2024) conducted a cohort in Glioblastoma (n=180). Metabolic syndrome vs. No metabolic syndrome was evaluated on Median overall survival (months) (p=0.085). Metabolic syndrome was not significantly associated with overall survival in patients with glioblastoma, with a median survival of 19.7 months versus 17.7 months in those without the syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: